Quantcast
Last updated on April 20, 2014 at 14:04 EDT

American Oriental Bioengineering Announces Change in Independent Auditor

August 11, 2009

NEW YORK, Aug. 11 /PRNewswire-Asia-FirstCall/ — American Oriental
Bioengineering, Inc. (NYSE: AOB), (“the Company” or “AOBO”), a pharmaceutical
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter (“OTC”)
products in China, announced today that the Audit Committee of the Board of
Directors of AOBO approved the engagement of Ernst & Young Hua Ming (“EY”) as
the Company’s independent registered public accounting firm for the year
ending December 31, 2009.

During the years ended December 31, 2007 and 2008 and through August 10,
2009
, there were no disagreements with the Company’s prior independent auditor,
Weinberg & Company, P.A., on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Weinberg, would have
caused Weinberg to make reference to the subject matter of the disagreements
in its reports on the consolidated financial statements for such years.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company
dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter
products in China.

SOURCE American Oriental Bioengineering, Inc.


Source: newswire